Intermediatemolecular

X-Chromosome Inactivation

Overview

Female mammals silence one X chromosome per cell (lyonization) to equalize X dosage with XY males: the inactive X condenses into the Barr body. The XIST long non-coding RNA coats the chosen X, recruiting Polycomb and silencing machinery. Inactivation is random per cell, making females mosaics (tortoiseshell cats, anhidrotic ectodermal dysplasia patches); skewed inactivation modifies X-linked disease severity.

Learning objectives

  • Explain why X-inactivation is needed
  • Describe XIST's role in silencing
  • Explain mosaicism and its visible examples
  • Describe skewed inactivation's clinical effects

The dosage problem

XX females have double the X-gene dose of XY males. Without compensation, X-gene overexpression would be lethal (as most autosomal trisomies are). Mammals solve it by silencing one X; flies double male X transcription; worms halve hermaphrodite X expression: three evolutions, one problem.

Dosage compensation

Equalizing X expression between sexes is as essential as the genes themselves.

XIST paints the X

The X-inactivation center's XIST gene produces a long non-coding RNA that coats its chromosome of origin in cis, recruiting SPEN, Polycomb (H3K27me3), and heterochromatin machinery. The chromosome collapses into the Barr body (visible at the nuclear periphery). Discovered by Mary Lyon (1961) from mouse coat-color mosaics.

Mary Lyon's hypothesis

1961: one X is randomly inactivated per cell, explaining mottled phenotypes in heterozygous female mice.

Mosaicism

Random inactivation per embryonic cell makes every female a mosaic: tortoiseshell/calico cats (orange/black X-linked alleles), sweat-gland patches, retinal mosaics revealing X-linked disease carriers. Once chosen, the state is clonally inherited: patches, not salt-and-pepper.

Escapees exist

~15% of human X genes escape inactivation (notably in pseudoautosomal regions), needing Y homologs in males.

Skewed inactivation

Usually 50:50, but chance or selection skews ratios; extreme skewing can unmask X-linked mutations in carrier females (severe hemophilia or DMD in rare skewed carriers) or protect them. XIST mutations and X-autosome translocations also skew.

Carriers vary

Skewing explains why some X-linked 'carriers' show symptoms: their active X is disproportionately the mutant one.

Key points

  • One X per female cell is silenced (Barr body) for dosage compensation
  • XIST lncRNA coats and silences the chosen X via Polycomb
  • Random inactivation makes females mosaic (calico cats)
  • Skewed inactivation modifies X-linked disease in carriers

Common misconceptions

✗ Myth: Males inactivate an X too.

✓ Truth: XY males have one X: nothing to silence. (XXY Klinefelter males do inactivate one.)

✗ Myth: The inactive X is gene-empty.

✓ Truth: ~15% of genes escape, and the X is gene-rich: silencing it is a massive regulatory feat.

Practice questions

Q1. X-inactivation is triggered by
  1. SRY
  2. XIST lncRNA coating the X
  3. Testosterone
  4. Meiosis
Answer: B.

XIST recruits silencing complexes to its chromosome in cis.

Q2. Tortoiseshell coat color demonstrates
  1. Incomplete dominance
  2. X-inactivation mosaicism
  3. Polygenic inheritance
  4. Imprinting
Answer: B.

Random X silencing per cell creates orange/black patches.

Q3. Skewed X-inactivation in a carrier female can cause
  1. Nothing ever
  2. Manifestation of the X-linked disorder
  3. Y-linked traits
  4. Extra chromosomes
Answer: B.

If mostly the mutant X stays active, carriers show disease.

Click a question to reveal the answer and explanation.

Frequently asked questions

Why are calico cats almost always female?

Orange/black coat alleles are X-linked; only XX mosaics show both colors. Rare XXY or chimeric males excepted.

What is the Barr body?

The condensed inactive X visible at the nuclear rim in interphase female cells (used in pre-DNA sex testing).

Can X-inactivation be reversed?

Experimentally yes in some contexts (iPSC reprogramming reactivates Xi); therapeutically, reactivating the good X is a strategy for Rett syndrome.